Desire starts in the brain. Let’s wake it up.

PT-141 is bremelanotide, a peptide that acts on melanocortin receptors in the brain involved in sexual desire and arousal. The FDA-approved version is an injection for premenopausal women with acquired, generalized HSDD. Rebody’s troche and nasal spray are compounded, needle-free formats.

Blood-flow medications act on the body’s physical response. PT-141 works through melanocortin signaling in the brain, a pathway involved in the desire and arousal that come before the physical response.

Rebody offers 1 mg and 2 mg mini troches in 8-count, 30-day packages. First-month pricing is shown with each strength.

Let the troche dissolve under the tongue or between gum and cheek. Your prescription label will list the strength, timing, and maximum frequency.

The phase 3 trials studied a 1.75 mg injection for 24 weeks. Rebody’s mini troche is a compounded format that dissolves under the tongue or between gum and cheek.

People with uncontrolled high blood pressure or known cardiovascular disease should not use the FDA-approved injection. Its label also covers temporary blood-pressure increases, heart-rate decreases, nausea, focal hyperpigmentation, pregnancy, and drug interactions.

Yes. Complete the private online intake for clinician review. If prescribed, your label will include the exact directions, strength, storage, and refill timing.